Skip to main content
. 2021 Dec 18;107(5):1441–1460. doi: 10.1210/clinem/dgab888

Figure 2.

Figure 2.

Figure 2.

Recommendations for prevention of antiresorptive agent-related osteonecrosis of the jaw in patients taking bone-modifying agents (BMA) due to A, osteoporosis, and B, cancer. ONJ, osteonecrosis of the jaw; RCT, randomized controlled trial. *In the absence of RCT.